Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by C. O'Hear
MA15.02 Long-Term Safety and Clinical Activity Results From a Phase Ib Study of Erlotinib Plus Atezolizumab in Advanced NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Related publications
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination With Chemotherapy in Asian Patients With Advanced Solid Tumors: Phase Ib Study
Targeted Oncology
Cancer Research
Oncology
Pharmacology
Mp78-07 Clinical Characteristics Associated With Early Progression or Long-Term Response From the Phase Ii Imvigor210 Study: Atezolizumab in Locally Advanced or Metastatic Urothelial Carcinoma
Journal of Urology
Urology
P1.01-54 a Phase I/Ib Study of Binimetinib (MEK162), a MEK Inhibitor Plus Carboplatin/Pemetrexed in Non-Squamous NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Long-Term Safety and Efficacy of Tocilizumab in Patients With Early Rheumatoid Arthritis of Moderate or High Activity (Results of Phase Iii Multicenter Extension Clinical Study Ml28124)
Nauchno-Prakticheskaya Revmatologiya
Rheumatology
Allergy
Immunology
MA04.09 Neoadjuvant Atezolizumab in Resectable Non-Small Cell Lung Cancer (NSCLC): Updated Results From a Multicenter Study (LCMC3)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Gemcitabine Plus Carboplatin in Patients With Advanced Hepatocellular Carcinoma: Results of a Phase II Study
ISRN Oncology
P1.01-02 Long-Term Outcomes With First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up From CheckMate 012
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary